Olle Ringdén

Research interests

Publications

• Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines

  Trends in Molecular Medicine · 2019 · 10.1016/j.molmed.2018.12.006

• Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

  Blood · 2015 · 10.1182/blood-2015-04-639831

• Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

  Transplantation and Cellular Therapy · 2014 · 10.1016/j.bbmt.2014.10.021

• Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?

  Stem Cells · 2012 · 10.1002/stem.1111

• Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70004-9

• Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation

  Stem Cells · 2012 · 10.1002/stem.1118

• Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy

  Transplantation and Cellular Therapy · 2011 · 10.1016/j.bbmt.2011.07.023

• Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

  The Lancet · 2008 · https://doi.org/10.1016/s0140-6736(08)60690-x

• Immunomodulation by mesenchymal stem cells and clinical experience

  Journal of Internal Medicine · 2007 · 10.1111/j.1365-2796.2007.01844.x

• Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells

  Leukemia · 2007 · 10.1038/sj.leu.2404777

• No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients

  Haematologica · 2007 · 10.3324/haematol.11446

• Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

  Transplantation · 2006 · https://doi.org/10.1097/01.tp.0000214462.63943.14

• Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms

  Experimental Cell Research · 2005 · 10.1016/j.yexcr.2004.12.013

• Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta

  Transplantation · 2005 · 10.1097/01.tp.0000159029.48678.93

• Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation

  Transplantation and Cellular Therapy · 2005 · 10.1016/j.bbmt.2005.01.005

• Mesenchymal Stem Cells Inhibit the Expression of CD25 (Interleukin‐2 Receptor) and CD38 on Phytohaemagglutinin‐Activated Lymphocytes

  Scandinavian Journal of Immunology · 2004 · 10.1111/j.0300-9475.2004.01483.x

• Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

  The Lancet · 2004 · https://doi.org/10.1016/s0140-6736(04)16104-7

• Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex

  Scandinavian Journal of Immunology · 2003 · https://doi.org/10.1046/j.1365-3083.2003.01176.x

• Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells

  Transplantation · 2003 · 10.1097/01.tp.0000082540.43730.80

• HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells

  Experimental Hematology · 2003 · https://doi.org/10.1016/s0301-472x(03)00110-3

• Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells

  Blood · 2000 · 10.1182/blood.v95.3.807.003k24_807_814

• Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

  PubMed · 2000 · 10.1182/blood.v95.12.3702

• A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group

  Blood · 1994 · 10.1182/blood.v83.9.2723.2723

• Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation

  Blood · 1990 · 10.1182/blood.v75.12.2459.2459

• Graft-versus-leukemia reactions after bone marrow transplantation

  Blood · 1990 · https://doi.org/10.1182/blood.v75.3.555.555

Current projects

No projects listed.